Shots: REGEN-COV neutralizes the SARS-CoV-2 B.1.1.7 variants, identified in the UK & SA. The data was included in a bioRxiv paper and submitted for peer-reviewed publication on the changing resistance […]readmore
Shots: The ongoing P-III trial involves assessing REGEN-COV (casirivimab & imdevimab) in 2000+ participants used as a passive vaccine to prevent COVID-19. An exploratory analysis, conducted on the first ~400 […]readmore
Shots: The company reported encouraging initial data from an ongoing P-I/II/III trial of its casirivimab + imdevimab (8,000/2,400mg) in hospitalized COVID-19 patients requiring low-flow oxygen. The results passed the futility […]readmore
Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple […]readmore
Copyright © 2020 Digiqole. All Right Reserved.